购物车
- 全部删除
- 您的购物车当前为空
Berberine ursodeoxycholate (HTD1801) 是一种口服有效的降血脂剂 ,是 Berberine 和 Ursodeoxycholic acid 的一种离子盐。Berberine ursodeoxycholate 具有广泛的代谢活性,可显著降低肝脏脂肪含量。Berberine ursodeoxycholate 可用于研究高脂血症、非酒精性脂肪性肝炎 (NASH) 和糖尿病。
Berberine ursodeoxycholate (HTD1801) 是一种口服有效的降血脂剂 ,是 Berberine 和 Ursodeoxycholic acid 的一种离子盐。Berberine ursodeoxycholate 具有广泛的代谢活性,可显著降低肝脏脂肪含量。Berberine ursodeoxycholate 可用于研究高脂血症、非酒精性脂肪性肝炎 (NASH) 和糖尿病。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 397 | 现货 | |
5 mg | ¥ 745 | 现货 | |
10 mg | ¥ 1,190 | 现货 | |
25 mg | ¥ 2,380 | 现货 | |
50 mg | ¥ 3,820 | 现货 | |
100 mg | ¥ 5,430 | 现货 | |
200 mg | ¥ 7,420 | 现货 |
产品描述 | Berberine ursodeoxycholate (HTD1801) is an orally effective hypolipidemic agent, an ionic salt of Berberine and Ursodeoxycholic acid.Berberine ursodeoxycholate has a wide range of metabolic activity and significantly reduces liver fat content. Berberine ursodeoxycholate has been used in studies of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes. |
体内活性 | Berberine ursodeoxycholate (BUDCA) tested in this phase 2 study (1000 mg twice a day) results in a significant reduction in liver fat content after 18 weeks of treatment. This improvement in liver fat content is associated with improvement in glycemic control, the apparent improvement in hepatic inflammation and injury with reductions in serum levels of liver associated enzymes, significant weight loss, and modest reductions in serum lipid levels.[1] |
别名 | 小檗碱熊去氧胆酸盐, HTD1801, BUDCA |
分子量 | 727.93 |
分子式 | C44H57NO8 |
CAS No. | 1868138-66-2 |
Smiles | COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC.[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC([O-])=O |
密度 | no data available |
存储 | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50.00 mg/mL (68.69 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容